CCXI - ChemoCentryx Brings Hope To Vasculitis Patients Steroid Therapy Can Play A Smaller Role
ChemoCentryx (CCXI) and its partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP) announced that they had achieved positive results from the phase 3 study treating patients with ANCA-associated vasculitis using the drug Avacopan. What makes these results substantial is that patients currently take high levels of steroid therapy, which is not ideal in terms of side effects. Avacopan has the opportunity to change the scope of treatment paradigm against this particular autoimmune disease. Not only that, but based on the most recently released late-stage study results, it appears as though this drug can